Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025
- Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
July 10, 2025
- PMDA to Clarify Position on Japanese PI Trials at August Symposium amid Industry Confusion
July 10, 2025
- J-ENTRY Consortium Steps Up to Develop Two “Drug Loss” Products
July 9, 2025
- Vyjuvek Gel, 1st Topical Gene Therapy, Poised for Approval in Japan
July 8, 2025
- Japan Panel Backs Shift to PCV20 for Pneumococcal Vaccination in Elderly
July 8, 2025
- AMED to Promote Earlier Out-Licensing to Industry to Bridge the “Devil’s River”: New Chief
July 8, 2025
- Semaglutide, Tirzepatide, and More Drugs under PMDA Safety Review
July 7, 2025
- Japan to Overhaul Diabetes Trial Guidelines to Align with Global Standards and Prevent Drug Lag/Loss
July 7, 2025
- Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
July 4, 2025
- Upper House Campaign Begins in Japan, Healthcare and Pharma-Linked Candidates in Spotlight
July 3, 2025
- Ex-Health Minister Takemi Vows to Bolster Japan’s Drug Development and Supply Resilience
July 2, 2025
- MHLW Shuffles Senior Bureaucrats, Miyamoto to Head Pharma Safety Bureau
July 2, 2025
- LDP’s Honda Pledges Strong Support for Pharma Sector via Pro-Innovation Pricing and Supply Stabilization
July 2, 2025
- Japan Publishes 2025 Strategy Report on Clinical Trials, Backs Single IRB as General Rule
July 1, 2025
- Average Annual Pay for PMDA Staffers at 7.99 Million Yen in FY2024
July 1, 2025
- LDP’s Furukawa Vows Policy Support for Domestic Innovation in New Modalities
June 30, 2025
- MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
- Japan Hands Out Orphan Tags to Ultragenyx’s Setrusumab and Lots More
June 30, 2025
- Japan Launches Public-Private Council to Create Innovation Ecosystem
June 27, 2025
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…